CFH rs3753396: Understanding Your Genetic Variant
The rs3753396 variant is a single-nucleotide polymorphism located within the CFH gene, which plays a critical role in the body's immune response. Research has associated this specific genetic marker with systemic complement activation and susceptibility to age-related macular degeneration (AMD).
What each genotype means
Typical complement activation
This genotype represents the reference sequence for this variant. Research indicates that individuals with this genotype do not carry the specific genetic signal associated with increased systemic complement activation levels linked to this site.
This is the most common genotype across most global populations.
Intermediate complement activation
Carrying one copy of the G allele is associated with higher levels of systemic complement activation compared to those without it. This variant is located in the CFH gene, which plays a key role in regulating the immune system's complement pathway.
This heterozygous genotype is found in a significant portion of the population, with the G allele frequency ranging between 0.30 and 0.45 in many groups.
Elevated complement activation
Individuals with two copies of the G allele show the strongest statistical association with increased systemic complement activation levels. While this variant is linked to complement regulation, it is not a diagnostic marker for disease; please discuss any concerns regarding eye health or inflammatory conditions with your clinician.
This genotype is common, appearing in a substantial fraction of individuals across diverse ancestral backgrounds.
What is rs3753396?
The rs3753396 variant is a specific change in the DNA sequence of the CFH gene, located on chromosome 1. In genetics, a single-nucleotide polymorphism (SNP) like rs3753396 represents a position where one of the four chemical bases—adenine (A), thymine (T), cytosine (C), or guanine (G)—differs between individuals. This particular variant is found within the CFH gene, which provides instructions for making a protein called complement factor H. Because this gene is located in a region of the genome known to be involved in immune regulation, scientists study these variations to understand how they might influence the body's inflammatory processes. It is important to note that having a specific genotype at this location does not mean an individual will develop a disease; rather, it is one of many factors that researchers study to understand biological susceptibility to certain conditions.
The Role of the CFH Gene
The CFH gene encodes complement factor H, a protein that acts as a vital regulator of the complement system. The complement system is a part of the innate immune system that helps the body clear out pathogens and damaged cells. Under normal conditions, complement factor H prevents this system from becoming overactive and damaging the body's own healthy tissues. When the CFH gene contains certain variants, the resulting protein may function differently, potentially leading to an imbalance in how the complement system is activated. Because the eye is particularly sensitive to inflammation, researchers have focused heavily on the CFH gene's role in ocular health. By studying how variants like rs3753396 affect the regulation of this immune pathway, scientists hope to better understand the underlying mechanisms of conditions like age-related macular degeneration (AMD).
Research and Associations
Scientific studies, including genome-wide association studies (GWAS), have identified a link between rs3753396 and systemic complement activation. Research published in journals such as PubMed indicates that this variant is associated with variations in the C3d-to-C3 ratio, a marker of how active the complement system is in the blood. Furthermore, the CFH gene region is well-documented in the GWAS Catalog for its association with age-related macular degeneration. While the evidence for these associations is considered moderate, it is important to recognize that genetic risk is complex. Many factors, including age, smoking, and other genetic markers, contribute to the development of AMD. Current research is ongoing to determine how these genetic findings might eventually help clinicians select patients for specific therapies, such as complement-inhibiting treatments. If you are concerned about your eye health or treatment options, please discuss these findings with your ophthalmologist or healthcare provider.
What You Can Do With This Information
Understanding your genetic profile can be an educational experience, but it is not a substitute for professional medical advice. Genetic variants like rs3753396 are statistical markers, not diagnostic tools. They represent a small piece of a much larger puzzle that includes your environment, lifestyle, and overall health history. You cannot change your genotype, but you can use this information to have more informed conversations with your doctor. If you have received results regarding this variant, do not make any changes to your medical care or medication regimen based on this information alone. Always consult with a qualified clinician or pharmacist who can interpret your results in the context of your complete medical history. They can provide guidance on appropriate screenings, lifestyle adjustments, or clinical trials that may be relevant to your specific situation.
How common is this variant?
The rs3753396 variant is common, with a minor allele frequency typically ranging between 0.30 and 0.45 across various global ancestral groups.
Frequently asked questions
Is rs3753396 a diagnosis for AMD?
No, rs3753396 is not a diagnosis. It is a genetic variant associated with a statistical increase in risk for certain conditions, but it does not guarantee that an individual will develop any disease.
Should I get tested for this variant?
Genetic testing for specific SNPs is generally not recommended for the general population unless there is a specific clinical reason. Consult with a genetic counselor or your doctor to determine if testing is appropriate for your health needs.
Can I change my risk associated with this variant?
While you cannot change your DNA, you can manage your overall health through lifestyle choices such as not smoking and maintaining a healthy diet. Discuss personalized risk management strategies with your healthcare provider.
Does this variant affect how I respond to medication?
Some research suggests that variants in the CFH gene may influence the response to certain therapies, such as anti-VEGF treatments. Always discuss your specific treatment plan and any concerns about medication response with your ophthalmologist.
Sources & further reading
Educational information only, last refreshed 9/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs3753396?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CFH
This regulatory variant in the CFH locus is linked to complement system dysregulation and is a recognized genetic risk factor for age-related macular degeneration.
This variant in the complement factor H gene is associated with altered regulation of the alternative complement pathway and increased susceptibility to age-related macular degeneration.
Intronic single nucleotide variant in the CFH region associated with susceptibility to age-related macular degeneration (AMD).
Common variant in the CFH locus strongly associated with risk of age-related macular degeneration (AMD).
Intronic marker in CFH forming critical susceptibility haplotypes for choroidal neovascularization and macular atrophy.
Intergenic/intronic variant within the CFH cluster contributing to phenotypic variation in retinal complement activation.